If it is December, then it is time for the San Antonio Breast Cancer Symposium, where more than 9,000 scientists, doctors, advocates, pharmaceutical representatives, and medical device companies from around the world gather to talk about breast cancer.

The meeting today started with a fascinating talk by Valerie Beral, an epidemiologist from the United Kingdom. She is responsible for the Million Women Study, which was one of the first studies to suggest that there were risks associated with using hormone replacement therapy (HRT).

She opened her talk with something that I have been thinking a lot about lately: the variations in cancer risk in different parts of the world. She noted that a woman’s lifetime risk of getting breast cancer by age 70 if she lives in rural Africa is 1 percent, whereas if she lives in a Western country, like the U.S., it is 6.3 percent.

Dr. Beral went on to show that most of the difference was a result of reproductive factors–such as age of first pregnancy, number of pregnancies, duration of breast feeding–and nutritional factors, such as high BMI, height, and physical activity. Both oral contraceptives and HRT increase the incidence of breast cancer once, but the risk goes back to a normal rate within five years of stopping either medication. She went on to say that in Westernized countries we are all at high risk, and that it is random who actually gets breast cancer. Her recommendation was that we develop a treatment to mimic the hormones of pregnancy to prevent breast cancer.

While I really respect Dr. Beral, I think she left out part of the story.  I doubt that the reproductive factors cause breast cancer. My guess is that they affect the local environment around the breast cells that either suppresses or makes cancer thrive. What initially causes the cells to mutate and become cancer cells are still unknown. They could be viral (my bias), environmental, hereditary, or all of the above. I must say I would rather find the cause and eliminate it than try to manipulate women’s bodies to mimic pregnancies—which is what the new Health of Women Study that the Love/Avon Army of Women is launching aims to do!

The other interesting reports were on the use of bisphosphonates (like Fosamax) for osteoporosis prevention and treatment. Researchers affiliated with the Women’s Health Initiative reported that they found a 30 percent decrease in the risk of breast cancer in the women who took bisphosphonates. A second case control study from Israel showed a similar result after a year on a bisphosphonate. Neither of these studies were randomized, controlled trials. In fact, they were not even designed to answer this question, so the data have to be considered preliminary. It also needs to be taken into account that women who have osteoporosis tend to have had less estrogen exposure, and women with less estrogen exposure tend to have a lower risk of breast cancer.

To determine whether bisphosphonates really do decrease breast cancer risk, investigators will need to do a randomized controlled study that enrolls an equal numbers of women who are at low and high risk of developing breast cancer. Still, I think this result is very interesting. If true, it is likely that the bisphosphonates are not killing cancer cells but rather affecting the local neighborhood around the cells so that it suppresses the cancer cells rather than stimulating them. Certainly, this is interesting.

Researchers also discussed an interesting new drug that appears to prevent bone metastases. The drug denosumab appears to be somewhat better than Zometa (zoledronic  acid) with the same side effects.

Another study showed that, as we have learned before, more is not always better. This time, we learned that adding the hormonal treatment fulvestrant (brand name faslodex) to an aromatase inhibitor was not better than using an aromatase inhibitor alone.
The final presentation discussed research looking at the use of MRI in women with BRCA1 and BRCA2. The study showed that MRI added to mammography surveillance results in a “stage shift” compared to mammography alone. This means that it leads to cancers being diagnosed at an earlier stage. This was an interesting study, but because the control group was not followed in a single center or in a screening program, it’s hard to know what the findings really mean.

Stay tuned for Day 2!

Share →

12 Responses to San Antonio Breast Cancer Symposium

  1. Sandi says:

    Typo Alert: The drug denosumab appears to be somewhat better than Zoladex (zoledronic acid) with the same side effects.

    I think you meant that it is better than Zometa…..

    Thanks for blogging the conference!

  2. Beth says:

    Thank you for the summary of the conference. Your blog is one of the best sources of understandable information and highlights surrounding the conference.

  3. Kathy says:

    Curious to know if you think insurance companies might now cover Zometa use for pre-menopausal early breast cancer patients,based on this new research??

  4. Maria says:

    Thank you for your summaries.

  5. mskcc cheats says:

    for a summary of ETHICS and SAFETY concerns at a high profile cancer research center (mskcc), please see: http://www.mskccheats.blogspot.com

    “Sloan is pursuing a systemic approach to reducing expenses and increasing revenues (..) One example of this is DISCOURAGING TERMINALLY ILL PATIENTS from seeking initial treatment or second opinions from the cancer center (..) the admission of such patients is counterproductive (..) to Sloan Kettering.” [Paraphrasing salient features, MSKCC (a 'not for profit' organization), CFO/Chief Financial Officer]

    VP Ed Mahoney currently heads MSKCC Facilities Management Department. MSKCC’s Facilities team built a laboratory building strewn with toxins and knowingly did NOT install ductwork controls. MSKCC had to permanently ABANDON a building after its employees were chronically exposed to poison (carbon monoxide).

    Attorney Shelly Friedman represents MSKCC when the Institute attempts to assuage a rightfully concerned local Community and its Board (cb8m) relative to Environmental Health and Safety concerns.

    Dr. Sarah Danishefsky is the Administrative Manager of the Bioorganic Chemistry Laboratory.

    Why would a non-clinician instruct a coworker to withhold (embargo) known information relative to the availability of clinical trial candidates available at MSKCC, yet created by competitors (e.g. Novartis and/or BristolMS) when the candidate from the lab she bean counts for has not yet left the proverbial clinical trials starting gate?

    MSKCC, we hoped you’d be our hero.
    MSKCC, minimally, you’re supposed to care.
    MSKCC, shame on you.
    Boo.
    You know better.

  6. Rose says:

    I didn’t see any reference to thermography as an early indicator of breast abnormalities. From what I have read this procedure has been perfected and should be used in conjunction with (not as a substitute for) mammograms.

  7. Mary says:

    Just diagnosed with triple negative and spots??? on liver and lungs and this site is VERY HELPFUL…in terms of the clinical trial information.

  8. I am regular reader, how are you everybody? This article posted at this website is
    really pleasant.

  9. Heather says:

    It’s going to be end of mine day, however before ending I am reading this impressive post to increase my experience.

  10. walter white says:

    Hi there! I could have sworn I’ve visited this web site before but after browsing
    through many of the articles I realized it’s new to me.

    Anyhow, I’m definitely happy I came across it
    and I’ll be book-marking it and checking back regularly!

  11. The fact right here is that you have to really like yourself and really want to get fit and wholesome.
    If you can’t do that, your diet is going to
    fail.

  12. weed grinder says:

    She sketched a firefighter in full gear holding a hose to cover this horrible and
    badly scarred tattoo. It is a traditional bong with a combination of water bongs and glass.
    There will be price reduction for buying more products.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>